These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 15176649

  • 1. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis.
    Zhou H, Buckwalter M, Boni J, Mayer P, Raible D, Wajdula J, Fatenejad S, Sanda M.
    Int J Clin Pharmacol Ther; 2004 May; 42(5):267-76. PubMed ID: 15176649
    [Abstract] [Full Text] [Related]

  • 2. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H, Mayer PR, Wajdula J, Fatenejad S.
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [Abstract] [Full Text] [Related]

  • 3. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 4. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
    Zhou H.
    J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
    [Abstract] [Full Text] [Related]

  • 5. Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis.
    Zhou SY, Shu C, Korth-Bradley J, Raible D, Palmisano M, Wadjula J, Fatenejad S, Bjornsson T.
    J Clin Pharmacol; 2011 Jun; 51(6):864-75. PubMed ID: 20852002
    [Abstract] [Full Text] [Related]

  • 6. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, Burge DJ.
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.
    Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC.
    Clin Pharmacol Ther; 2003 Apr; 73(4):348-65. PubMed ID: 12709725
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of etanercept dose reduction in patients with rheumatoid arthritis using pharmacokinetic/pharmacodynamic modeling and simulation.
    Hsu LF, Huang JD.
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):776-86. PubMed ID: 24887337
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.
    Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H.
    J Clin Pharmacol; 2005 Mar; 45(3):246-56. PubMed ID: 15703360
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 11. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.
    J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
    [Abstract] [Full Text] [Related]

  • 12. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

  • 13. Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis.
    Martín-Mola E, Sieper J, Leirisalo-Repo M, Dijkmans BA, Vlahos B, Pedersen R, Koenig AS, Freundlich B.
    Clin Exp Rheumatol; 2010 Sep; 28(2):238-45. PubMed ID: 20483046
    [Abstract] [Full Text] [Related]

  • 14. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 15. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 16. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis.
    Lee J, Noh JW, Hwang JW, Oh JM, Kim H, Ahn JK, Lee YS, Cha HS, Koh EM.
    Clin Rheumatol; 2010 Oct; 29(10):1149-54. PubMed ID: 20683738
    [Abstract] [Full Text] [Related]

  • 17. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.
    Borrás-Blasco J, Gracia-Pérez A, Casterá MD, Rosique-Robles JD, Abad J.
    Expert Opin Biol Ther; 2013 Aug; 13(8):1103-8. PubMed ID: 23675687
    [Abstract] [Full Text] [Related]

  • 18. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J, Hernández MV, Rosario V, Ruiz-Esquide V, Cabrera-Villalba S, Ramírez J, Cañete JD, Sanmartí R.
    Reumatol Clin; 2014 Aug; 10(1):10-6. PubMed ID: 23876791
    [Abstract] [Full Text] [Related]

  • 19. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers.
    Gu N, Yi S, Kim TE, Kim J, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2011 Dec; 33(12):2029-37. PubMed ID: 22088414
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of rhTNFR-Fc in healthy Chinese volunteers and in Chinese patients with Ankylosing spondylitis.
    Fang Y, Li LJ, Wang R, Huang F, Song HF, Tang ZM, Li YZ, Guan HS, Zheng QS.
    Acta Pharmacol Sin; 2010 Nov; 31(11):1500-7. PubMed ID: 20953211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.